Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206700 · ClinicalTrials.gov registry record · Phase 2
Open-label Trial of Leukine in Active Crohn's Disease
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 378
- Enrollment target
NCT00206700: Clinical Trial Phase 2 study, sponsored by Genzyme, a Sanofi Company.
NCT00206700 is a Phase 2 study that was terminated before completion, run by Genzyme, a Sanofi Company. The registered enrollment target is 378 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (184% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206700, a Phase 2 study, was terminated before completion, sponsored by Genzyme, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 378 participants
- Enrollment target
Study Summary
The purpose of this study is to establish a safety profile sargramostim administered in 8 week cycles to adult patients with active Crohn's disease.
Interventions
- DRUG Sargramostim (Leukine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 378 participants |
| Start Date | 2003-02 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Why NCT00206700 stopped before completion
NCT00206700 is an interventional study that assigns participants to a tested intervention. The registered 378 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (184% higher).
The record links to 0 conditions, and to 1 intervention - of which Sargramostim (Leukine) is the first listed.
NCT00206700 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00206700 about?
NCT00206700 is a clinical study titled "Open-label Trial of Leukine in Active Crohn's Disease". The purpose of this study is to establish a safety profile sargramostim administered in 8 week cycles to adult patients with active Crohn's disease.
What is the current status of trial NCT00206700?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 378 participants. The study started on 2003-02. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00206700?
The interventions under investigation include: Sargramostim (Leukine) (DRUG).
Who is sponsoring clinical trial NCT00206700?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00206700's enrollment target sits among peer trials
378 115th of 2000 higher than 1,886 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04254185 · 378 participants · NA
Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow
- NCT06616584 · 378 participants · Phase 2
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- NCT07024784 · 377 participants · Phase 2
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia